Welcome to Vimpat. This site is screen reader friendly.

Skip to content Skip to main navigation Skip to footer navigation

Proven with the broadest range of second- and first-generation AEDs,
Vimpat offers the power to treat adult patients with partial-
onset seizures.¹

Vimpat has shown a greater reduction in seizure frequency and seizure reduction by half or more versus placebo, as well as long-term tolerability benefits and no known clinically significant pharmacokinetic drug-drug interactions. In clinical studies, Vimpat was generally well tolerated with adverse events that were typically mild-to-moderate and dose-related. Please see below for Important Safety Information about Vimpat

Learn More About the Power of Vimpat >

Register Now and Stay Informed

Keep up to date on Vimpat and other advances in antiepileptic therapy from UCB, The Epilepsy Company^™.

Help Your Patients Save Money on Vimpat

Your patients can save up to $360 in a year with the Vimpat Patient
Savings Program.

Print Savings Card >

Get Trial Samples of Vimpat

Your patients might benefit from the demonstrated seizure reduction power of Vimpat.

Get Samples >

Indication

Vimpat^® (lacosamide) tablets and oral solution are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy who are 17 years and older. Vimpat injection is indicated as short-term replacement when oral administration is not feasible in these patients.

Important Safety Information

Warnings and Precautions

AEDs increase the risk of suicidal behavior and ideation. Patients taking Vimpat should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Patients should be advised that Vimpat may cause dizziness, ataxia, and syncope. Caution is advised for patients with known cardiac conduction problems, who are taking drugs known to induce PR interval prolongation, or with severe cardiac disease. In patients with seizure disorders, Vimpat should be gradually withdrawn to minimize the potential of increased seizure frequency. Multiorgan hypersensitivity reactions have been reported with antiepileptic drugs. If this reaction is suspected, treatment with Vimpat should be discontinued.

Vimpat oral solution contains aspartame, a source of phenylalanine. A 200-mg dose of Vimpat oral solution (equivalent to 20 mL) contains 0.32 mg of phenylalanine.

Common Adverse Reactions

The most common adverse reactions occurring in ≥10 percent of Vimpat-treated patients, and greater than placebo, were dizziness, headache, nausea, and diplopia.

Dosage adjustments are recommended for patients with mild or moderate hepatic impairment or severe renal impairment. Use in severe hepatic impairment patients is not recommended.

Please see Vimpat Prescribing Information.